Loading
PSMC2 (26S proteasome regulatory subunit 7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.00, clinical 0.99).
In plain words · PSMC2 (26S proteasome regulatory subunit 7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
PSMC2 (26S proteasome regulatory subunit 7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins.
No product in this corpus aims at PSMC2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA lists PSMC2 among essential proteins and finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA PSMC2: RNA low tissue specificity; high antibody staining in 24 normal tissues; highest cancer staining testis cancer (11 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (plasma cell myeloma, mantle cell lymphoma). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas PSMC2 tissue; Open Targets ENSG00000161057 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Shibuya et al, Nature, 1992, "New human gene encoding a positive modulator of HIV Tat-mediated transactivation". Source.
Sources: HGNC HGNC:9548 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P35998 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000161057 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: plasma cell myeloma 0.60, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0))
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. PSMC2 belongs to the heterohexameric ring of AAA (ATPases associated with diverse cellular activities) proteins that unfolds ubiquitinated target proteins that are concurrently translocated into a proteolytic chamber and degraded into peptides. Location: Cytoplasm (UniProt). Locus 7q22.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Appendix, Bone marrow, Bronchus, Duodenum, Endometrium, Epididymis, Fallopian tube, Gallbladder.
Medium only: carcinoid.
HPA PSMC2 tissue · HPA PSMC2 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PSMC2" OR ABSTRACT:"PSMC2" OR TITLE:"proteasome 26S subunit, ATPase 2" OR ABSTRACT:"proteasome 26S subunit, ATPase 2" OR TITLE:"26S proteasome regulatory subunit 7" OR ABSTRACT:"26S proteasome regulatory subunit 7" OR TITLE:"MSS1" OR ABSTRACT:"MSS1" OR TITLE:"S7" OR ABSTRACT:"S7" OR TITLE:"Nbla10058" OR ABSTRACT:"Nbla10058") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PSMC2, not a curated reading list.